Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deferred Tax LiabilityNon-Current Deferred Tax LiabilityNotes PayablesOperating LeasesOther Non-Current AssetsPayablesPreferred SharesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Iovance Biotherapeutics (IOVA) Non-Current Deffered Revenue (2017 - 2018)

Iovance Biotherapeutics has reported Non-Current Deffered Revenue over the past 2 years, most recently at $230000.0 for Q4 2018.

  • Quarterly results put Non-Current Deffered Revenue at $230000.0 for Q4 2018, down 22.56% from a year ago — trailing twelve months through Dec 2018 was $230000.0 (down 22.56% YoY), and the annual figure for FY2018 was $230000.0, down 22.56%.
  • Non-Current Deffered Revenue for Q4 2018 was $230000.0 at Iovance Biotherapeutics, down from $297000.0 in the prior quarter.
  • Over the last five years, Non-Current Deffered Revenue for IOVA hit a ceiling of $297000.0 in Q4 2017 and a floor of $230000.0 in Q4 2018.